BioAge Labs, Inc. ( (BIOA) ) has released its Q3 earnings. Here is a breakdown of the information BioAge Labs, Inc. presented to its investors.

Initiated Phase 2 STRIDES trial of azelaprag in combination with tirzepatide for obesityCompleted $238.3 million initial public offering and ...

Septerna's protracted initial public offering (IPO) on the Nasdaq has finally reached its conclusion, with the final amount ...

Not only are deals going off at higher valuations than the companies initially anticipated, but the prices have been popping after the stocks began trading in the public markets. Observers are hoping ...

Our round-up of financings in the biotech sector this week is led by BioAge Lab's filing of an initial public offering (IPO), with a placeholder target of $100 million, plus sizeable private ...

2024 Weight-loss drug developer BioAge raises $198 mln in U.S. IPO September 26, 2024 Obesity drug developer BioAge Labs aims up to $640 mln valuation in upsized US IPO September 25, 2024 Obesity ...

Shares of BioAge Labs (BIOA), a biopharmaceutical company focused on obesity drugs, opened 25% above its initial public offering (IPO) price on Thursday. RICHMOND, Calif., Sept. 25, 2024 (GLOBE ...

Drug developers have achieved resounding success in the fall U.S. IPO market, with all the $100-million plus offerings since September upsized. Robust debuts by drug developers Bicara Therapeutics , ...

(Reuters) -Goldman Sachs-backed drug developer Septerna said on Thursday it was seeking a valuation of $743.1 million in its ...

END OF THE WEEK PERFORMANCE: RECENT IPOS TO WATCH: BioAge (BIOA), Innovation Beverage ... UPCOMING IPOS: Upcoming IPO and ...

BioAge Labs is a new kid on the block. The company completed its initial public offering (IPO) on Oct. 1. The biotech's leading candidate is called azelaprag. It is being developed as a weight ...